Roche to acquire US firm Poseida Therapeutics

Roche to acquire cell therapy maker Poseida Therapeutics in $1.5 bln deal
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion
Roche said it will acquire Poseida Therapeutics at $9.00 per share, representing a total equity value of approximately $1.0 billion, with performance provisions which would take the full deal value to around $1.
Poseida Therapeutics (PSTX) Soars After Merger Announcement with Roche
In an exciting development for shareholders and the biotechnology industry alike, Poseida Therapeutics, Inc. (Nasdaq: PSTX) has seen its stock price surge by an impressive 221.68%, reaching $9.20 in premarket trading on Tuesday.
Roche to acquire Poseida Therapeutics
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche.
Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
Switzerland's Roche will acquire U.S. biopharma firm Poseida Therapeutics in a cash deal worth up to $1.5 billion, the companies said on Tuesday. Poseida is to be bought at $9 per share in cash, and stockholders will also receive a non-tradeable contingent value right for up to $4 per share if specific milestones are met,
Roche In $1.5 Bn Deal To Buy Poseida Therapeutics
Swiss pharmaceutical giant Roche said on Tuesday it agreed to buy US biopharma firm Poseida Therapeutics for $1.5 billion (1.4 billion euros) -- but Roche shares dipped over a disappointing study on a key lung cancer treatment.
Healthcare giant Roche set to purchase Poseida Therapeutics
Swiss healthcare giant Roche is set to acquire US-based Poseida Therapeutics in a deal that values Poseida at about $1 billion. The transaction is expected to close in the first quarter of 2025. Roche said on Tuesday it would start a tender offer to acquire Poseida's outstanding shares for $9 per share in cash at closing,
Yahoo1d
Roche to acquire Poseida Therapeutics for $1.5bn
Roche has signed an agreement to acquire Poseida Therapeutics in a $1.5bn deal. The transaction includes Poseida's clinical ...
Poseida shares triple on Tuesday, boosted by Roche collaboration
Roche is buying Poseida Therapeutics for about $1.5 billion. The deal values Poseida stock at a massive premium.
The 10 Best La Roche-Posay Products for Every Skin Concern, Tested by Editors
The brand came to develop products specifically designed for dermatologists and skin care professionals to treat patients ...
Get Beauty Editor-Like Skin With These 10 La Roche-Posay Products
The best La Roche-Posay skincare products, including anti-aging options and picks for acne-prone, oily, dry, mature, ...
FiercePharma7d
Roche files patent suit to fend off potential Evrysdi generics from Zydus, Natco
Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are ...
La Roche-Posay Set Sights High Before Turning 50
PARIS - As it readies to celebrate its 50th birthday next year, the world's largest dermatological skin care brand La ...
pharmaphorum7d
Roche buys diabetes app developer mySugr
including any devices which may directly compete with Roche products. Extra financial resources from the acquisition will go toward recruitment, product improvement, and building more ...
FiercePharma5d
Roche's Vabysmo shows potential to treat eye disorder common in Asia
Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...